Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population

Completed · Phase 4

Conditions studied: Psoriasis, Atopic Dermatitis

In brief

The purpose of this study is to determine the effect of Pandel® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either psoriasis or atopic dermatitis involving greater than 20% body surface area.

Key facts

Study ID

NCT01137032

Run by

Fougera Pharmaceuticals Inc.

People needed

19

Starts

2004-06-01

Expected to finish

2005-08-01

Last updated by the study team

2016-05-04

Who can join

Age: 0 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of psoriasis or atopic dermatitis involving more than 20% of body surface area
• Good health with the exception of psoriasis or atopic dermatitis

You may not qualify if…

• Any disease affecting the HPA-axis
• Subjects who are pregnant, nursing, or planning a pregnancy within the study participation period

Where it is running

• Christopher Huerter, MD — Omaha, Nebraska, United States
• Oswald Mikell, MD — Hilton Head Island, South Carolina, United States
• Michael Gold, MD — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.